Dear Member,

We know that fitting a high-quality New Medicine Service (NMS) into a busy dispensing workflow is a challenge. However, the NMS remains one of our most valuable tools for both patient safety and pharmacy sustainability.

As we move into Week 4 of our clinical series and the first for this year, we are shifting our focus to two "silent" conditions. These are therapy areas where patients often feel no immediate benefit from their medication but may experience significant barriers to adherence - making your intervention the deciding factor in their long-term health.

The “Silent” 

This week, we are providing expert-level support sheets for:

• Lipid Management (Hypercholesterolaemia): Bridging the gap between "invisible" protection and the "Nocebo effect" of muscle pain.
• Osteoporosis (Bisphosphonates): Engineering adherence for complex administration rules and preventing "The Silent Fracture.”

Why focus on these this week? Both Osteoporosis and Lipid management suffer from high "Stoppage Rates" in the first 6 months. Patients often stop statins because of negative media or stop bisphosphonates because the "upright rule" is a chore. Your consultation is the clinical pivot point that keeps these patients protected.

Please review the attached guides and use them to streamline your consultations and drive your service numbers up.

Mandatory Clinical Disclaimer: Pharmacists must always verify information against current sources. The materials provided in this series are visual training aids designed for educational purposes only. They should not be relied upon to make clinical decisions. Professional clinical judgement must be exercised at all times, and the latest SPC, BNF, and NICE guidelines must be consulted. The authors accept no liability for clinical errors.

Series Catch-Up: Previous Modules Sent to Date

To ensure your team has a complete clinical library, here is a brief recap of the high-impact modules we have already covered in this series:

• Heart Failure: Focus on the "Initiation Titration" and monitoring for electrolyte imbalances with ACEi/Beta-Blockers.
• Epilepsy: Managing the "Bioequivalence" of different brands and the critical importance of a zero-miss dose policy.
• Parkinson’s: Engineering the "On/Off" phenomenon and the necessity of strict timing for Levodopa doses.
• Hypertension: Navigating the "Triple Whammy" (ACEi + Diuretic + NSAID) and managing the ACEi dry cough.
• Anticoagulation: Safety-netting for major bleeds and explaining the short half-life of DOACs compared to Warfarin.
• Depression: Bridging the "Suicide Window"—the dangerous period where physical energy returns before mood improves.

Regards,

PharmaPlus